HK Stock Market Move | TENNOR THERAP-B (06872) surged over 15% in morning trading. Positive proof-of-concept data from its Phase IIa trial of rifapentine. Phase IIb clinical trial approved and set to commence.

TENNOR THERAP-B (06872) rose over 15% in early trading. As of the time of writing, it is up 4.46%, priced at HKD 175.5, with a trading volume of HKD 14.22 million. In terms of news, on September 7, Danor Pharmaceuticals announced that the Phase IIa proof-of-concept clinical trial for its globally pioneering three-target new drug, Rifacquinone (TNP-2092), which is injected into the joint cavity for the treatment of prosthetic joint infection (PJI), has yielded positive topline results. Based on this proof-of-concept data, a multi-center Phase IIb clinical trial has been approved by the National Medical Products Administration and will be officially launched soon. It is noteworthy that on September 7, the Shenzhen Stock Exchange announced that, in accordance with the relevant regulations of the "Implementation Rules for the Shenzhen-Hong Kong Stock Connect," the list of securities eligible for Hong Kong Stock Connect has been adjusted, effective from September 7. Among them, Danor Pharmaceuticals has been included in the Hong Kong Stock Connect list. This inclusion is expected to help broaden the shareholder base, attract long-term institutional investors, and enhance the liquidity of the stock.